AKRO (Akero Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AKRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-09 | Yuan Xu | Director | D | — | — |
| 2025-12-09 | Tomas J. Heyman | Director | D | — | — |
| 2025-12-09 | Jonathan Young | Chief Operating Officer | D | — | — |
| 2025-12-09 | Jane Henderson | Director | D | — | — |
| 2025-12-09 | Mark T Iwicki | Director | D | — | — |
| 2025-12-09 | Scott A. Gangloff | Chief Technology Officer | D | — | — |
| 2025-12-09 | Patrick Lamy | See Remarks | D | — | — |
| 2025-12-09 | G. Walmsley Graham | Director | D | — | — |
| 2025-12-09 | William Richard White | Chief Financial Officer | D | — | — |
| 2025-12-09 | Andrew Cheng | President and CEO | D | — | — |
| 2025-12-09 | Catriona Yale | Chief Development Officer | D | — | — |
| 2025-12-09 | Timothy Rolph | Chief Scientific Officer | D | — | — |
| 2025-12-09 | Seth Loring Harrison | Director | D | — | — |
| 2025-12-09 | Chou Judy | Director | D | — | — |
| 2025-11-28 | Timothy Rolph | Chief Scientific Officer | M | — | — |
| 2025-11-26 | Jonathan Young | Chief Operating Officer | MIXED | — | — |
| 2025-11-21 | Andrew Cheng | President and CEO | G | — | — |
| 2025-11-19 | Timothy Rolph | Chief Scientific Officer | G | — | — |
| 2025-11-13 | Andrew Cheng | President and CEO | G | — | — |
| 2025-11-06 | Catriona Yale | Chief Development Officer | M | — | — |
| 2025-10-14 | Andrew Cheng | President and CEO | MIXED | — | — |
| 2025-10-10 | G. Walmsley Graham | Director | M | — | — |
| 2025-10-09 | Andrew Cheng | President and CEO | M | — | — |
| 2025-10-09 | Timothy Rolph | Chief Scientific Officer | MIXED | — | — |
| 2025-10-03 | Jonathan Young | Chief Operating Officer | MIXED | — | — |
| 2025-09-12 | Catriona Yale | Chief Development Officer | Sell | — | — |
| 2025-09-12 | William Richard White | Chief Financial Officer | Sell | — | — |
| 2025-09-12 | Timothy Rolph | Chief Scientific Officer | Sell | — | — |
| 2025-09-12 | Andrew Cheng | President and CEO | MIXED | — | — |
| 2025-09-12 | Jonathan Young | Chief Operating Officer | Sell | — | — |
| 2025-09-10 | Timothy Rolph | Chief Scientific Officer | MIXED | — | — |
| 2025-09-04 | Jonathan Young | Chief Operating Officer | MIXED | — | — |
| 2025-08-19 | Scott A. Gangloff | Chief Technology Officer | M | — | — |
| 2025-08-13 | Jonathan Young | Chief Operating Officer | MIXED | — | — |
| 2025-08-13 | Andrew Cheng | President and CEO | Sell | — | — |
| 2025-08-12 | Jane Henderson | Director | MIXED | — | — |
| 2025-08-07 | Timothy Rolph | Chief Scientific Officer | MIXED | — | — |
| 2025-07-18 | Catriona Yale | Chief Development Officer | MIXED | — | — |
| 2025-07-11 | Andrew Cheng | President and CEO | Sell | — | — |
| 2025-07-09 | Timothy Rolph | Chief Scientific Officer | MIXED | — | — |
| 2025-07-03 | Patrick Lamy | Senior VP, Commercial Strategy | Sell | — | — |
| 2025-07-02 | Andrew Cheng | President and CEO | A | — | — |
| 2025-07-02 | Timothy Rolph | Chief Scientific Officer | A | — | — |
| 2025-07-02 | Catriona Yale | Chief Development Officer | A | — | — |
| 2025-07-02 | Patrick Lamy | Senior VP, Commercial Strategy | A | — | — |
| 2025-07-02 | William Richard White | Chief Financial Officer | A | — | — |
| 2025-07-02 | Scott A. Gangloff | Chief Technology Officer | A | — | — |
| 2025-07-02 | Jonathan Young | Chief Operating Officer | A | — | — |
| 2025-06-20 | William Richard White | Chief Financial Officer | Sell | — | — |
| 2025-06-20 | Scott A. Gangloff | Chief Technology Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,297,318 | — |
| — | 10%+ Owner | 5,830,203 | — |
| — | Director | 3,954,858 | — |
| — | 10%+ Owner | 3,940,534 | — |
| — | 10%+ Owner | 3,309,616 | — |
| — | — | 3,271,829 | — |
| — | 10%+ Owner | 3,229,548 | — |
| — | 10%+ Owner | 3,160,319 | — |
| — | 10%+ Owner | 3,118,638 | — |
| — | 10%+ Owner | 3,033,552 | — |
| — | 10%+ Owner | 2,706,412 | — |
| — | 10%+ Owner | 743,802 | — |
| — | 10%+ Owner | 505,099 | — |
| — | 10%+ Owner | 404,079 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKRO quote page; the site-wide leaderboard is on the insider transactions hub.